| Market Cap | 116.89B | P/E | 14.87 | EPS this Y | 0.70% | Ern Qtrly Grth | 92.50% |
| Income | 7.92B | Forward P/E | 11.61 | EPS next Y | 5.70% | 50D Avg Chg | -7.00% |
| Sales | 26.19B | PEG | 7.20 | EPS past 5Y | 5.67% | 200D Avg Chg | -12.00% |
| Dividend | 4.00% | Price/Book | 21.86 | EPS next 5Y | 1.72% | 52W High Chg | -26.00% |
| Recommedations | 2.70 | Quick Ratio | 2.62 | Shares Outstanding | 534.33M | 52W Low Chg | 3.00% |
| Insider Own | 0.22% | ROA | 8.15% | Shares Float | 533.20M | Beta | 0.64 |
| Inst Own | 79.83% | ROE | 252.78% | Shares Shorted/Prior | 7.59M/7.99M | Price | 218.76 |
| Gross Margin | 74.93% | Profit Margin | 30.23% | Avg. Volume | 2,381,219 | Target Price | 254.55 |
| Oper. Margin | 36.83% | Earnings Date | Aug 2 | Volume | 1,707,862 | Change | -0.91% |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| Oppenheimer | Outperform | May 18, 23 |
| RBC Capital | Sector Perform | May 9, 23 |
| Barclays | Underweight | May 1, 23 |
| Piper Sandler | Overweight | Apr 28, 23 |
| Oppenheimer | Outperform | Apr 24, 23 |
| Barclays | Underweight | Apr 14, 23 |
| Wells Fargo | Overweight | Mar 13, 23 |
| Truist Securities | Hold | Feb 13, 23 |
| SVB Leerink | Market Perform | Feb 2, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Develo.. SVP, Business Development | Nov 09 | Sell | 292.90 | 387 | 113,352 | 6,630 | 11/10/22 |
| Grygiel Nancy A. | SVP & CCO SVP & CCO | Nov 05 | Sell | 293.54 | 545 | 159,979 | 13,009 | 11/08/22 |
| Williams R Sanders | Director Director | Aug 22 | Sell | 249.96 | 200 | 49,992 | 5,301 | 08/22/22 |
| ECKERT ROBERT | Director Director | Aug 18 | Sell | 248.9966 | 6,600 | 1,643,378 | 21,184 | 08/19/22 |
| ECKERT ROBERT | Director Director | Aug 10 | Option | 85.59 | 20,000 | 1,711,800 | 34,575 | 08/12/22 |
| Williams R Sanders | Director Director | May 23 | Sell | 250.00 | 600 | 150,000 | 5,501 | 05/23/22 |
| Graham Jonathan P | EVP, Gen. Counsel &.. EVP, Gen. Counsel & Secy. | May 10 | Sell | 241.8114 | 13,500 | 3,264,454 | 37,333 | 05/10/22 |
| SUGAR RONALD D | Director Director | May 12 | Option | 71.64 | 1,000 | 71,640 | 16,927 | 05/12/21 |
| SUGAR RONALD D | Director Director | May 12 | Sell | 250.59 | 1,000 | 250,590 | 15,927 | 05/12/21 |
| Grygiel Nancy A. | SVP & CCO SVP & CCO | May 12 | Sell | 252.51 | 2,500 | 631,275 | 12,461 | 05/12/21 |
| Grygiel Nancy A. | SVP & CCO SVP & CCO | May 12 | Option | 162.6 | 2,500 | 406,500 | 14,961 | 05/12/21 |
| SUGAR RONALD D | Director Director | Apr 15 | Option | 71.64 | 1,000 | 71,640 | 16,927 | 04/15/21 |
| SUGAR RONALD D | Director Director | Apr 15 | Sell | 249.98 | 1,000 | 249,980 | 15,927 | 04/15/21 |
| SUGAR RONALD D | Director Director | Mar 10 | Option | 71.64 | 1,000 | 71,640 | 16,805 | 03/10/21 |
| SUGAR RONALD D | Director Director | Mar 10 | Sell | 231.53 | 1,000 | 231,530 | 15,805 | 03/10/21 |
| Bradway Robert A | Chairman, CEO and Pr.. Chairman, CEO and President | Feb 22 | Option | 54.69 | 73,500 | 4,019,715 | 618,380 | 02/22/21 |
| REESE DAVID M | EVP, Research and De.. EVP, Research and Development | Feb 16 | Option | 54.69 | 2,300 | 125,787 | 42,059 | 02/16/21 |
| SUGAR RONALD D | Director Director | Feb 10 | Option | 71.64 | 1,000 | 71,640 | 16,805 | 02/10/21 |
| SUGAR RONALD D | Director Director | Feb 10 | Sell | 238.4 | 1,000 | 238,400 | 15,805 | 02/10/21 |
| SUGAR RONALD D | Director Director | Jan 14 | Option | 71.64 | 1,000 | 71,640 | 16,805 | 01/14/21 |
| SUGAR RONALD D | Director Director | Jan 14 | Sell | 235.99 | 1,000 | 235,990 | 15,805 | 01/14/21 |